RVC Biofund
In June 2010 the Board of Directors of RVC has approved the Conceptual Framework of RVC Biofund. In early 2011, the fund started its operations.
The Biofund was necessitated by a low share of Russian innovative drugs, amounting today to less than 1%. With virtually zero infrastructure to develop biopharma and medical start-ups, foreign services devour 50% to 80% of Russian investment resources. To remedy this, RVC BioFund will be investing capital into service companies of this cluster and biotech start-ups. Additionally, it will be launching an ecosystem to generate and incubate as many biotech projects as possible.
The Fund focus covers innovative biopharma companies and service companies providing contract, laboratory, analytical and consulting services to biotechnological, pharmaceutical and medical companies.
Key Parameters
• Full title: RVC Biopharmaceutical Investments, ltd.
• Abbreviated title: RVC BioFund.
• Initial capital: RUB 500 mln.
• Target capital: RUB 1,5 bln.
• Fund life: unlimited.
• Biofund will be co-investing capital in synergy with private investors.
• Biofund will cover up to 75% of capital demand from service companies and up to 50% of capital demand from innovative biopharma companies. Contributions will be made in form of cash, property or intellectual property rights to an amount not exceeding RUB 100 mln during Round One.
• Biofund tolerates any legal or financial terms allowed by Russian laws.
• Biofund welcomes projects directly from innovators as well as private investors (without using the venture partner system).
• Investment decisions are taken by the Investment Committee.
• Director of Biofund — Egor Beketov.
• A project pitch must take form of a brief summary highlighting its key parameters.
Form of Summary
Summary requirements (russian).
You are welcome to direct your questions and submit your summaries to: info@rvcbio.ru
Contact Details
1 Leninskie Gory, bld 75b, Moscow, 119992, Russia
Moscow State University Science Park.
Phone: +7(495) 930-8504